Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In Southeast Asia, some types of the malaria parasite develop resistance to the drug combinations used to cure and prevent the disease. If this drug resistance spread to Africa, it’d be a disaster. Fortunately, partners on the front lines are finding ways to fight back. Watch this video about the amazing work our team of SMRU researchers is doing to combat drug resistance in Thailand.

The Shoklo Malaria Research Unit (SMRU) was established in 1986 as a centre for epidemiological study into the treatment and prevention of resistant malaria among refugee camps on the Thai-Burma border. At the time, malaria was the most serious health problem facing the displaced population living along the border and the primary cause of death, representing over 45% of out-patient consultations.

Currently 130,000 people live in refugee camps along the Thai-Burma border. The work carried out by SMRU over the past 20 years has improved therapeutics for malaria and relegated malaria from being the single most important medical problem in these camps, to a rare cause of illness and death amongst refugees.

Researchers at SMRU continue to monitor, treat and control malaria, both within the camps and amongst the communities of Burmese migrant workers, who live outside the camps.

Video transcript

It’s one of the most stunning things to say that this little mosquito kills almost a million people every year. Most of those deaths are from malaria. We study mosquitoes in the lab where we grow them, and researchers, volunteers taking their own arm in and feeding them with their own blood. One of the partners and foundations we work with is the Shoklo Malaria Research Unit in Thailand.

When you are infected with malaria, you can take drugs that clear it from your body. Our best drug, artemisinin combination therapy ACT, unfortunately right now in Southeast Asia we are seeing resistance emerge. And that's very scary because if that mutation left Southeast Asia and moved to Africa, in the place where most malaria deaths take place, and where these new drugs being so valuable, they will stop working. A child experiencing cerebral malaria is an awful thing to watch because their brain is being damaged, and they have seizures, and you have to move very quickly. I’ve been in those wards, you can see the sweatiness, that incredible fever that the child’s experiencing.

Along the Myanmar Thailand border, many people work in the forest. These workers often are bringing malaria back at home. One thing that's confusing about malaria, is if you've been exposed enough, your symptoms go way way down, yet we want to cure those people, so that they're not a source of the disease. We've got a team of health workers called the malaria elimination task force, and they are on the frontline. They’re trying to find the cases and treat everyone.

I'm Gilles Delmas, I’m the director of the Malaria Elimination Task Force. Years ago, there were lots of malaria cases. Anybody around here would have several malaria attacks in a year, sometimes more than one a month. The situation has got much better, and the transmission is much lower than what it was. The problem is that the medicines we're using now to control malaria, to treat the patients, are showing signs of resistance, and we know that within the next two to five years, the medicines we’re using now will be useless.

So the world is investing in these workers in Southeast Asia to go find malaria and get rid of it. If we can get rid of it there, it won't have a chance to spread to other locations. We reach out to the people and communities, creating health post workers. These are people who don't have medical training, they're just local villagers who volunteer to help out with this effort. They receive kits with the diagnostic equipment, and the local people trust them. They know them and if the test comes back positive, they'll be able to give them the drugs immediately. In the areas where malaria parasite factions are very very hot, or even asking some villages all of the people there to take the drug to clear out the malaria. If we do it with the right coverage level, malaria will die out in that region. If we do this well, we’ll stop drug resistant malaria from spreading, and we’ll learn how you can get rid of malaria in villages, and use that on a global basis.

There’s just so many mosquitoes.

Similar stories

Ruam Thai Phatthana 2 Clinic Officially Opens in Phop Phra District

The Ruam Thai Phatthana 2 (RTS) Clinic was officially opened on 24 September 2026 in Ruam Thai Subdistrict, Phop Phra District, Tak Province, marking a new chapter in healthcare services for communities along the Thailand–Myanmar border.

Francois Nosten on Fever Pitch podcast, on a collapsing border where medicine meets war

Professor Francois Nosten, Director of MORU's Shoklo Malaria Research Unit (SMRU), reflects on the decades he’s spent on the border between Thailand and Myanmar, a place of relentless upheaval and quiet endurance. From the 1980s onward, he has lived amid war, displacement, and disease, building a fragile bridge between science and survival. He characterizes the border as a wound that never quite closes – people cross not for opportunity but to escape a state that devours its own. What he describes is not steady progress but a cycle of collapse and recovery, every advance shadowed by the return of violence and the onset of disease.

SMRU’s ‘TB Village’: A lifeline for marginalised patients on the Thai–Myanmar border

In a settlement of bamboo cabins, among mango and jackfruit trees, the Shoklo Malaria Research Unit runs a secluded clinic known as 'TB Village.' Reachable only by dirt roads, this sanctuary provides critical treatment and quarantine for dozens of marginalized Burmese tuberculosis patients. Here, at SMRU, patients receive care for diseases like tuberculosis and malaria. The unit works to heal patients and prevent outbreaks from crossing borders, providing a lifeline of safety.

Research Spotlight: The IRONMUM Trial at SMRU

IRONMUM is one example of SMRU’s long-standing collaboration with global partners to address critical health challenges in low- and middle-income settings. Through partnerships with institutions such as the University of Oxford and the Mahidol Oxford Tropical Medicine Research Unit (MORU), SMRU conducts research that is firmly grounded in local realities, ensuring that preventive strategies and treatments are effective where they are needed most. Working on the Thailand–Myanmar border since 1986, SMRU combines research, clinical care, and humanitarian action to improve the health of mothers, children, and vulnerable populations affected by infectious diseases and limited access to healthcare.

Analysis of SMRU samples could lead to vaccine for multiple childhood infections

The first large-scale genomic exploration of H. influenzae, a bacteria that causes 200m infections per year in children worldwide, has revealed extensive antibiotic resistance and uncovered genetic clues that could help in future vaccine development, say researchers from Wellcome Sanger Institute, the Universities of Oxford and Oslo, and MORU’s Shoklo Malaria Research Unit (SMRU) and Cambodia-Oxford Medical Research Unit (COMRU).

Rose McGready honoured for her work to improve healthcare for Thai-Myanmar border communities

On 17 Nov at a ceremony in Canberra, Prof Rose McGready, Deputy Director of the Shoklo Malaria Research Unit (SMRU), was honoured with the 2026 ACT Australian of the Year Award for her extraordinary dedication over 30 years to improving healthcare for displaced and marginalised communities along the Thai-Myanmar border which, coupled with clinical and research work that has changed the treatment of malaria around the world, particularly for pregnant and breastfeeding women, has saved the lives of countless mothers and their babies.

Similar stories

Ruam Thai Phatthana 2 Clinic Officially Opens in Phop Phra District

The Ruam Thai Phatthana 2 (RTS) Clinic was officially opened on 24 September 2026 in Ruam Thai Subdistrict, Phop Phra District, Tak Province, marking a new chapter in healthcare services for communities along the Thailand–Myanmar border.

Francois Nosten on Fever Pitch podcast, on a collapsing border where medicine meets war

Professor Francois Nosten, Director of MORU's Shoklo Malaria Research Unit (SMRU), reflects on the decades he’s spent on the border between Thailand and Myanmar, a place of relentless upheaval and quiet endurance. From the 1980s onward, he has lived amid war, displacement, and disease, building a fragile bridge between science and survival. He characterizes the border as a wound that never quite closes – people cross not for opportunity but to escape a state that devours its own. What he describes is not steady progress but a cycle of collapse and recovery, every advance shadowed by the return of violence and the onset of disease.

SMRU’s ‘TB Village’: A lifeline for marginalised patients on the Thai–Myanmar border

In a settlement of bamboo cabins, among mango and jackfruit trees, the Shoklo Malaria Research Unit runs a secluded clinic known as 'TB Village.' Reachable only by dirt roads, this sanctuary provides critical treatment and quarantine for dozens of marginalized Burmese tuberculosis patients. Here, at SMRU, patients receive care for diseases like tuberculosis and malaria. The unit works to heal patients and prevent outbreaks from crossing borders, providing a lifeline of safety.

Research Spotlight: The IRONMUM Trial at SMRU

IRONMUM is one example of SMRU’s long-standing collaboration with global partners to address critical health challenges in low- and middle-income settings. Through partnerships with institutions such as the University of Oxford and the Mahidol Oxford Tropical Medicine Research Unit (MORU), SMRU conducts research that is firmly grounded in local realities, ensuring that preventive strategies and treatments are effective where they are needed most. Working on the Thailand–Myanmar border since 1986, SMRU combines research, clinical care, and humanitarian action to improve the health of mothers, children, and vulnerable populations affected by infectious diseases and limited access to healthcare.

Analysis of SMRU samples could lead to vaccine for multiple childhood infections

The first large-scale genomic exploration of H. influenzae, a bacteria that causes 200m infections per year in children worldwide, has revealed extensive antibiotic resistance and uncovered genetic clues that could help in future vaccine development, say researchers from Wellcome Sanger Institute, the Universities of Oxford and Oslo, and MORU’s Shoklo Malaria Research Unit (SMRU) and Cambodia-Oxford Medical Research Unit (COMRU).

Rose McGready honoured for her work to improve healthcare for Thai-Myanmar border communities

On 17 Nov at a ceremony in Canberra, Prof Rose McGready, Deputy Director of the Shoklo Malaria Research Unit (SMRU), was honoured with the 2026 ACT Australian of the Year Award for her extraordinary dedication over 30 years to improving healthcare for displaced and marginalised communities along the Thai-Myanmar border which, coupled with clinical and research work that has changed the treatment of malaria around the world, particularly for pregnant and breastfeeding women, has saved the lives of countless mothers and their babies.